Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene, Strand, Elsevier MDL, BioDiscovery, Inpharmatica, Ingenuity, Columbia Bioinformatics Center, Helyxzion, Tripos


Stratagene to Pay Strand $4M in Software Collaboration

Stratagene will pay Strand Life Sciences approximately $4 million over the next two years as part of a software-development collaboration that the companies entered late last year, according to a 10-K filing with the US Securities and Exchange Commission this week [BioInform 12-12-05].

Stratagene said in the 10-K filing that it has agreed to make "aggregate milestone payments of $900,000 to Strand upon our acceptance of certain deliverables," as well as $1.5 million in minimum annual payments to Strand in the first 12 months after its first commercial sale or 60 days after its final acceptance of the product that Strand is developing.

This minimum annual payment may be offset by $500,000 of the milestone payments in the first 12 months, however.

In addition, Stratgene has agreed to pay Strand $1.7 million in minimum annual payments in the second 12 months of the agreement.

Stratagene also disclosed in the 10-K that it has reached an "amicable settlement" in its arbitration with Ariadne Genomics regarding their distribution agreement for Ariadne's PathwayAssist software [BioInform 10-24-05].

In October, the companies "executed a binding settlement agreement term sheet to resolve all of their disputes, and the parties are in the process of completing a comprehensive settlement agreement," Stratagene said, adding that the companies "have been unable to resolve certain remaining issues."

Stratagene said that Ariadne has paid it $300,000 under the settlement agreement, but did not disclose additional terms.

Elsevier MDL Cross-Links DiscoveryGate with PubChem

Elsevier MDL said last week that it has integrated its DiscoveryGate platform with the National Institutes of Health's PubChem database of small-molecule data.

PubChem is now cross-indexed with the Compound Index hosted on DiscoveryGate, the company said.

DiscoveryGate now includes links that connect researchers to information from PubChem, while researchers using PubChem can link to additional information in DiscoveryGate if they have the appropriate licenses.

The deal builds upon an agreement the organizations entered late last year in which Elsevier MDL deposited around 2,500 structures from its xPharm database of pharmacological activity into PubChem [BioInform 12-26-05].

BioDiscovery Opens European Sales Center in The Netherlands

BioDiscovery said this week that it has opened a European sales and support center in the Netherlands.

The El Segundo, Calif.-based company said in a statement that it has had a "presence" in Europe for more than eight years, but that it "realized the need for a direct sales and support organization that had a significant understanding of our technology as well as the European market."

The center will be locally managed by TouchDown Biomarketing, which is based in Bemmel and offers sales and marketing and technical and logistical support to life sciences companies to launch their products or services into the European market.

Inpharmatica and Ingenuity to Co-Market Software

Inpharmatica and Ingenuity Systems have penned a co-marketing alliance for their drug-discovery software, the companies said this week.

Terms of the agreement call for Inpharmatica to co-market its Blu-Chip probe-to-protein assignment module with the Ingenuity Pathway Analysis system, and vice-versa.

The alliance will enable researchers to move through two analysis steps: probe assignment for Affymetrix GeneChips and protein network analysis, the companies said.

Additional details were not disclosed.

Columbia Bioinformatics Center Deploys Collective Technologies' Data Center System

IT services firm Collective Technologies said this week that it has completed a data center consolidation project for Columbia University's Center for Computational Biology and Bioinformatics.

The system is based on Collective's Data Center LifeCycle Management Solution, which enabled C2B2 to consolidate five disparate data center locations in two separate buildings into a single data center in a new building on campus.

Financial terms of the agreement were not provided.

Helyxzion, Telomolecular Partner on Drug Development

Helyxzion, a bioinformatics company based in Madison, Wisc., has agreed to partner with nanotechnology firm Telomolecular on the development of therapies to treat aging and age-related disease, the companies said this week.

Helyxzion's bioinformatics platform specializes in identifying "errors unique to an individual's genome," the company said.

"By combining this capability with Telomolecular's specialized nanotechnologies and custom protein design it may be possible to safely deliver exceptionally large-molecules across human cell membranes that 'find and replace' undesirable genetic transformations known to contribute to cancer and human aging," the companies said.

Additional details were not disclosed.

Tripos Signs Chemistry Agreements with Cara Therapeutics, Abbott Labs

Tripos said this week that its UK-based medicinal chemistry group has signed a research collaboration agreement with Cara Therapeutics, a New York-based biotech startup focused on developing therapeutics for pain and inflammation.

Separately, Tripos said that it will collaborate with Abbott Laboratories to make compounds. The two firms will collaborate in library design, analysis and synthesis, according to a statement from the companies.

Financial details were not released for either agreement.

Filed under

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.